FTC gets NAD case
This article was originally published in The Tan Sheet
Advertising for PBM Products' Ultra Bright Beginnings infant formula will be referred to FDA and FTC since the company declined to participate in a NAD review, the National Advertising Division says March 24. The Council of Better Business Bureaus group requested substantiation for PBM's comparative superiority claims including "the highest DHA at a low price" and "more DHA than any brand." PBM also was asked to provide substantiation for implied claims that babies fed Bright Beginnings "will be smarter than babies fed with other formulas," NAD states...
You may also be interested in...
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.
Look! Up in the sky! It’s a bird! It’s a plane! It’s … a COVID-19 test from Quest Diagnostics.